Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRN23 in Adult Chinese Patients with XLH
NCT04842019Phase 4Completed
- Sponsor
- Kyowa Kirin
- Start
- Sep 2021
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of burosumab in X-linked hypophosphatemia (XLH), sponsored by Kyowa Kirin. Started Sep 2021; status: completed.
02
Drugs
burosumab
03
Conditions
X-linked hypophosphatemia (XLH)
Beyond the preview
Go deeper on NCT04842019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04842019.